DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Molecular Partners
Molecular Partners
Darpinstm the Next Generation of Protein Drugs MP0112 – the Best
Investor Presentation
Swiss Biotech Report – "Agility, Leadership and Innovation in the Time of COVID-19” – Is Indeed Appropriate
Molecular Partners Reports Key Financials for H1 19 and Corporate Highlights: EMA Has Validated the Marketing Authorization Appl
UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
Molecular Partners Reports Key Financials for FY 2019 and Corporate Highlights from Q4 2019
Switzerland's Biotech
Annual Report 2019
Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy
Allergan and Molecular Partners Announce Topline Safety Results from MAPLE Study of Abicipar Pegol
Making the Darpin® Difference Reality for Patients
Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of Its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers
Annual Report 2017 Molecular Partners AG
Unlock and Expand: Custom Built Biology for Patients
Syneos Health® Consulting Biopharma BD Newsletter
Longevity Industry in Switzerland
MEDIA RELEASE Interim Management Statement Q3 2020 Of
News Release
Top View
MP Corporate Presentation
News Release
Allergan and Molecular Partners Announce Two Positive Phase 3
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar Pegol in Neovascular Wet Age-Related Macular Degeneration
MEDIA RELEASE Molecular Partners Announces Collaboration With
Swiss Biotech Report 2020
Molecular Partners Reports Significant Progress of Pipeline and Preliminary Unaudited Key Financials for 2017 – Key Value Inflection Points in 2018
MEDIA RELEASE Molecular Partners Doses First Cohort in Phase 1 Trial
2020 Virtual Healthcare Conference
MEDIA RELEASE Molecular Partners to Share Preclinical and Clinical
Learner Notification Society for Immunotherapy of Cancer (SITC)
MP 1H 2018 Presentation and Webcast
COVID-19) News Feed
Swiss Biotech Report 2021 Digital Version Final LOWRES
First-In-Human Phase I Study of MP0250, a First-In-Class Darpin Drug Candidate Targeting VEGF and HGF, in Patients with Advanced
Darpin® Difference Reality for Patients
R&D Day 2019
Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for Ensovibep for the Treatment of COVID-19